<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(21)</volume><submitter>Yoo JW</submitter><pubmed_abstract>The wide application of next-generation sequencing (NGS) technologies has led to the discovery of multiple genetic alterations in pediatric acute lymphoblastic leukemia (ALL). In this work, we aimed to investigate the mutational spectrum in pediatric ALL. We employed a St. Mary's customized NGS panel comprising 67 leukemia-related genes. Samples were collected from 139 pediatric ALL patients. Eighty-five patients (61.2%) harbored at least one mutation. In B-cell ALL, the RAS pathway is the most involved pathway, and the three most frequently mutated genes were &lt;i>NRAS&lt;/i> (22.4%), &lt;i>KRAS&lt;/i> (19.6%), and &lt;i>PTPN11&lt;/i> (8.4%). &lt;i>NRAS&lt;/i> and &lt;i>PTPN11&lt;/i> were significantly associated with a high hyperdiploidy karyotype (&lt;i>p&lt;/i> = 0.018 and &lt;i>p&lt;/i> &amp;lt; 0.001, respectively). In T-cell ALL, the three most frequently mutated genes were &lt;i>NOTCH1&lt;/i> (37.5%), &lt;i>FBXW7&lt;/i> (16.6%), and &lt;i>PTEN&lt;/i> (6.2%). Several pairs of co-occurring mutations were found: &lt;i>NRAS&lt;/i> with &lt;i>SETD&lt;/i>, &lt;i>NRAS&lt;/i> with &lt;i>PTPN11&lt;/i> in B-cell ALL (&lt;i>p&lt;/i> = 0.024 and &lt;i>p&lt;/i> = 0.020, respectively), and &lt;i>NOTCH1&lt;/i> with &lt;i>FBXW7&lt;/i> in T-cell ALL (&lt;i>p&lt;/i> &amp;lt; 0.001). The most frequent newly emerged mutation in relapsed ALL was &lt;i>NT5C2&lt;/i>. We procured comprehensive genetic information regarding Korean pediatric ALL using NGS technology. Our findings strengthen the current knowledge of recurrent somatic mutations in pediatric ALL.</pubmed_abstract><journal>Journal of clinical medicine</journal><pagination>6298</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9658397</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Spectrum of Genetic Mutations in Korean Pediatric Acute Lymphoblastic Leukemia.</pubmed_title><pmcid>PMC9658397</pmcid><pubmed_authors>Kim S</pubmed_authors><pubmed_authors>Yoo JW</pubmed_authors><pubmed_authors>Lee JM</pubmed_authors><pubmed_authors>Kim Y</pubmed_authors><pubmed_authors>Jo S</pubmed_authors><pubmed_authors>Chung NG</pubmed_authors><pubmed_authors>Ahn A</pubmed_authors><pubmed_authors>Cho B</pubmed_authors><pubmed_authors>Kim M</pubmed_authors><pubmed_authors>Lee JW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Spectrum of Genetic Mutations in Korean Pediatric Acute Lymphoblastic Leukemia.</name><description>The wide application of next-generation sequencing (NGS) technologies has led to the discovery of multiple genetic alterations in pediatric acute lymphoblastic leukemia (ALL). In this work, we aimed to investigate the mutational spectrum in pediatric ALL. We employed a St. Mary's customized NGS panel comprising 67 leukemia-related genes. Samples were collected from 139 pediatric ALL patients. Eighty-five patients (61.2%) harbored at least one mutation. In B-cell ALL, the RAS pathway is the most involved pathway, and the three most frequently mutated genes were &lt;i>NRAS&lt;/i> (22.4%), &lt;i>KRAS&lt;/i> (19.6%), and &lt;i>PTPN11&lt;/i> (8.4%). &lt;i>NRAS&lt;/i> and &lt;i>PTPN11&lt;/i> were significantly associated with a high hyperdiploidy karyotype (&lt;i>p&lt;/i> = 0.018 and &lt;i>p&lt;/i> &amp;lt; 0.001, respectively). In T-cell ALL, the three most frequently mutated genes were &lt;i>NOTCH1&lt;/i> (37.5%), &lt;i>FBXW7&lt;/i> (16.6%), and &lt;i>PTEN&lt;/i> (6.2%). Several pairs of co-occurring mutations were found: &lt;i>NRAS&lt;/i> with &lt;i>SETD&lt;/i>, &lt;i>NRAS&lt;/i> with &lt;i>PTPN11&lt;/i> in B-cell ALL (&lt;i>p&lt;/i> = 0.024 and &lt;i>p&lt;/i> = 0.020, respectively), and &lt;i>NOTCH1&lt;/i> with &lt;i>FBXW7&lt;/i> in T-cell ALL (&lt;i>p&lt;/i> &amp;lt; 0.001). The most frequent newly emerged mutation in relapsed ALL was &lt;i>NT5C2&lt;/i>. We procured comprehensive genetic information regarding Korean pediatric ALL using NGS technology. Our findings strengthen the current knowledge of recurrent somatic mutations in pediatric ALL.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-25T23:22:06.734Z</modification><creation>2025-04-06T09:22:18.153Z</creation></dates><accession>S-EPMC9658397</accession><cross_references><pubmed>36362526</pubmed><doi>10.3390/jcm11216298</doi></cross_references></HashMap>